IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights Clarity's fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical trials First...
United Imaging Drives Forward Several Major Innovations in Multiple Imaging Modalities
The company's IPO and 20,000th global installation are followed by new technological innovations, in keeping with its commitments to the U.S. and other markets. HOUSTON, Nov. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, announced a series of commercially available and 510k pending technologies. In its 11th year, United...
Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs
NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that four abstracts highlighting CFI-402257 and CFI-400945, the Company's potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022 at...
Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified
Lunit becomes first software as a medical device (SaMD) company in APAC to become MDR CE and UKCA certified MDR and UKCA certifications are required for all Europe and UK commercial medical devices with implementation deadlines set to 2024 SEOUL, South Korea, Nov. 21, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a global provider of AI-powered cancer solutions, today...
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
Collaboration will bring together Umoja's iCIL platform and IASO's chimeric antigen receptors to create the next generation of broadly accessible, readily available cell therapies in indications that are significantly underserved by today's standards of care. SEATTLE, SAN JOSE, Calif., SHANGHAI and NANJING, China, Nov. 21, 2022 /PRNewswire/ -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics...
Mintal Tracker Lets Users See Their Dreams – Again
AI-driven feature automatically generates an image of the user's dream by utilizing key words, enabling the ability to physically share their dreams SUNNYVALE, Calif., Nov. 21, 2022 /PRNewswire/ -- Mintal Tracker, a sleep tracking app driven by artificial intelligence (AI) technology that offers a scientific approach to healthier sleep, announced an AI-generated art feature called "Draw My Dream," which...
Professor László Tabár Joins DetectedX as the Medical Director of Breast Cancer Imaging
DetectedX Bolsters Executive Team with Internationally Renowned Physician, Academic and Educator to Expand Breast Imaging Educational Content on the Company's Radiology Online Learning Platform SYDNEY, Nov. 21, 2022 /PRNewswire/ -- DetectedX, leaders in intelligent interactive educational technology, announced today that Professor László Tabár, a Nobel Prize Nominee and visionary physician, academic and educator,...
Triastek Receives FDA IND Clearance for 3D Printed Medicine for the Treatment of Ulcerative Colitis
Triastek's third FDA IND clearance for a 3D printed medicine T21, a novel potential treatment capable of colon-targeted drug delivery NANJING, China, Nov. 21, 2022 /PRNewswire/ -- Triastek, Inc. ("Triastek") a global healthcare company pioneering 3D printing of pharmaceuticals with its proprietary technology, Melt Extrusion Deposition (MED®), announced today that...
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against...
Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process...
